Takeaway
- Additional safety findings from the DARE-19 trial showed that dapagliflozin was well tolerated in patients with and without type 2 diabetes (T2D) hospitalized with COVID-19.
Why this matters
- Patients hospitalized with COVID-19 and having cardiometabolic comorbidities have an increased risk of developing serious complications, including multiorgan failure and death....
